DNA Repair Deficiency and Immunotherapy Response-Reference-Cited by-同舟云学术

DNA Repair Deficiency and Immunotherapy Response

Published:2018-06-10 Issue:17 Volume:36 Page:1710-1713
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Mouw Kent W.¹,D’Andrea Alan D.¹

Affiliation:

1. Kent W. Mouw, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; and Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.78.2425

Reference51 articles.

1. DNA Damage and Repair Biomarkers of Immunotherapy Response

2. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

3. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

4. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

5. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature;Histopathology;2024-07-29

2. Molecular Pathology of Urothelial Carcinoma;Clinics in Laboratory Medicine;2024-06

3. ER-positive and BRCA2-mutated breast cancer: a literature review;European Journal of Medical Research;2024-01-06

4. An overview of the research progress of BRCA gene mutations in breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07

5. Precision Medicine in Bladder Cancer: Present Challenges and Future Directions;Journal of Personalized Medicine;2023-04-28